VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
VolitionRx Limited, a Delaware corporation, filed this Current Report on August 13, 2026. The filing announces financial results and business updates for the quarter ended June 30, 2026. The company's common stock trades on the NYSE American under the symbol VNRX.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1.
Material Changes
No specific material changes or comparative financial data are detailed within the body of this filing. The document references a press release for the actual results and updates.
Guidance, Outlook, and Management Commentary
Management has scheduled a conference call for August 14, 2026, at 8:30 a.m. U.S. Eastern Time to discuss the results. The filing explicitly states that the information furnished is not "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly incorporated by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 financial figures.
- Listen to the conference call on August 14, 2026, for management commentary and guidance.
- Verify the company's cash position and burn rate in the full press release, as this filing contains no liquidity data.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the business updates.